The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
What is the NAV on this? This is really one to drip-feed because even at 30% more than NAV there is downside.
"Looking ok here today, while sat on a Portuguese beach looking at the peaches ha." I am a long time poser and do not post often. But I have to reply because this is very disturbing that you feel the need to check in here.
Longish thanks for the info, a wait for FY20 that I am happy to take. Or I could flip the situation and look to trade some until the end of the year with buys at 128p and a sell at 148p. Given the current dividend after the reset, this could be a good range?
I have been ignoring my VOD paper losses. For now, I have accepted Jefferies International pessimistic 144p target (1 year) given that we have had the reset and the dividend yield is 6%@130p. What would change my mind is some good numbers coming from somewhere and progressive dividend increases back to Deutsche Bank optimistic 1-year target of 240p! Not holding my breath but the key dates are: 26 July 2019 - Trading update for the quarter ending 30 June 2019 and 12 November 2019 Half-year results for the six months ending 30 September 2019. We will need to check back on these dates.
The answer was yes. The premium went quite low recently and now recovering to 7.23%. I was questioning the justification for a premium, but with no other way into the stocks on the portfolio then I remain in.
I would only consider getting back in at 10 to +25% to NAV. I was lucky I sold as soon as someone explained the odd NAV situation.
I would ignore smallcapjoy who will never understand free cash flow and that free cash flow here would have to more than half before the AA would be unable to meet repayments. I can't wait for Woodford to be out.
Sales of new cars are down over the last couple of years but from a record high of 2.7m in 2016. These sales fluctuations tend to average out over a number of years. Please view the chart:
https://www.bbc.co.uk/news/business-48747617
Please can someone help. Does the low NAV on their website include the £400m in cash?
What would be the indictive dividend percentage going forward at say 120p and how do did you work this one out?
Little shocked by my paper loss that now looks unrecoverable and the warrants worse than a joke. I hope the company will succeed and I will wait it out. On a positive most UK small biotechs are at historic lows. The science looks sounds and this video is a reminder...
https://www.ukinvestorshow.com/videos/valirx-plc/
Sorry I don't follow my stocks at all closely, could this be due to any dilution that would push him < 3%
Tricky to time this. I already have loads of UK PLC that I bought this time last year thinking there is a chance of Brexit direction while the small amount of tech and global funds are doing well. I am going to hold buying WPCT until after the summer as I see a lot of sideways movement.
I have to agree with hellyeah. The "strong free cash flow generation" has always been there and the debt (and speculative fundraising) is just an excuse for shorting on the Brexit uncertainty. Similar to the Vodafone situation and most of UK PLC. The UK globally is a good position for growth regardless of the outcome of Brexit. Fair value, in my opinion, sits at 150p+ and should this company ever pay off the debt long term we are looking at 500p. As always the market does not do long term and so anything can happen :-)
I just don't get the investors placing at lower and lower values knowing the next placing will be lower!
This means a deal is not imminent otherwise the placings would be done at a higher and then higher price.
So why do they keep investing?
This aside, for me, this punt is not about the money. One of my family members biopsy was clear of cancer this week and that what really matters. I may buy some another batch every year ans see.
"Up she goes. nice to see this one ticking up. Glad I added when I did."
-------
I hope to buy some more after the deal as I am not averaging down despite being underwater. Perhaps a week after the deal when the share price settles down. I don't know if I will be averaging up or down at that point but I will know at that point that Valirx has a future and be on the radar of investment companies.
I have never been a long term investor in VOD nor am I an income seeker. VOD remains though my bread and butter trading stock. Currently stuck on 185p (where I called the bottom!) with a view to average down after Brexit but remain divi reinvested.
*** European Journal of Drug Metabolism and Pharmacokinetics on VAL401 ***
https://link.springer.com/article/10.1007%2Fs13318-018-00538-4
I am sure you have all read up on the above. I apologise for posting again as I don't check these forums on a regular basis and I can not find any discussion on it as I am always late to these.
The conclusion of the article was overall positive on VAL401. Been thinking VAL401 must have been dead in the water but clearly wrong and there is potential. I am ever hopeful that VAL's drugs could be used not just to extend life but also used together with future cures for cancer.
We want to keep the directors accountable but at the same time ignore the paper loss and think of the greater good. I am and my view will not change.
Don't engage in arguments as any sniff of real success ends in shorters panic trading the stock price up. But it has to be a real success not just good news.
CHELSEA7, hang on, your timescales expectations for drugs (inc. VAL101) are unreasonable given that it similar time frame to others I have followed. I think it is the lack of information about progress in the 6-year gap that was poor. The reason for the decline and lack of institutional investment is some other unkown thing in my opinion.
IMHO this is a move by the BOD to show potential investors they have skin in the game. They are terrible on the finance side, why so greedily low? but I have faith in the science.
Onwards and sideways... and then up. (I hope)